close

Mergers and Acquisitions

Date: 2017-05-30

Type of information: Company acquisition

Acquired company: Pharmacell (The Netherlands)

Acquiring company: Lonza (Switzerland)

Amount: undisclosed

Terms:

  • • On May 30,2017, Lonza successfully completed the acquisition of PharmaCell, one of the most-respected cell and gene contract manufacturers in Europe with employees in Maastricht and Geleen (NL). Achelous Partners served as financial advisers to PharmaCell on the transaction. Boels Zanders acted as PharmaCell’s legal counsel.

Details:  

  • PharmaCell has been established in 2005 when cell manufacturing was still in its infancy. The company has since been the manufacturer of the only two European-approved commercial cell therapy products. PharmaCell has more than 6,000 m2 of GMP clean rooms, QC and other support spaces. In 2016 PharmaCell had sales of € 11 million.
  • PharmaCell was primarily selected due to its core expertise in autologous cell and gene therapy manufacturing, which includes experience with two commercial Advanced Therapy Medicinal Products (ATMPs)-licensed products. Autologous therapies use a patient’s own cells.
 

Related: Technology  - Services - Bioproduction - Manufacturing

Is general: Yes